Elanco Animal Health stock reaches 52-week high at 19.36 USD

Elanco Animal Health stock has reached a notable milestone, hitting a 52-week high at 19.36 USD. With a market capitalization of $9.58 billion, the company has demonstrated remarkable momentum, posting a 79.34% gain over the past six months and a 56.23% increase year-to-date. According to InvestingPro analysis, the stock appears slightly overvalued at current levels. The stock’s performance indicates strong investor confidence and positive market sentiment surrounding Elanco Animal Health’s business prospects. This 52-week high marks a period of growth and resilience for the company, which maintains a healthy current ratio of 2.6. For deeper insights into Elanco’s valuation and growth prospects, InvestingPro offers 12 additional investment tips and a comprehensive Pro Research Report.

In other recent news, Elanco Animal Health reported its second-quarter 2025 earnings, surpassing analysts’ expectations with an adjusted earnings per share of $0.26, compared to the forecasted $0.20. The company’s revenue reached $1.24 billion, exceeding the anticipated $1.18 billion. Elanco’s Credelio Quattro product achieved a significant milestone, hitting $100 million in net sales in less than eight months, marking it as the company’s fastest pet health blockbuster. The product has captured approximately 14% of the dollar share in broad-spectrum sales from U.S. veterinary clinics as of June. Additionally, Elanco is set to join the S&P MidCap 400 index, replacing Sarepta Therapeutics. This move follows Stifel’s decision to raise its price target on Elanco to $23.00 from $18.00, maintaining a Buy rating. Stifel’s analysis suggests that Credelio Quattro’s U.S. market share is expected to grow, contributing significantly to revenue growth in the coming years.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.